PD-1/PD-L1 Pathway: A Therapeutic Target in CD30+ Large Cell Lymphomas

Authors

Wei Xie
L Jeffrey Medeiros
Shaoying Li
Guilin Tang
Guang Fan
Jie Xu

Publication Date

7-4-2022

Journal

Biomedicines

DOI

10.3390/biomedicines10071587

PMID

35884893

PMCID

PMC9313053

PubMedCentral® Posted Date

7-4-2022

PubMedCentral® Full Text Version

Post-print

Abstract

The programmed death-ligands, PD-L1 and PD-L2, reside on tumor cells and can bind with programmed death-1 protein (PD-1) on T-cells, resulting in tumor immune escape. PD-1 ligands are highly expressed in some CD30+ large cell lymphomas, including classic Hodgkin lymphoma (CHL), primary mediastinal large B-cell lymphoma (PMBL), Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (EBV+ DLBCL), and anaplastic large cell lymphoma (ALCL). The genetic alteration of the chromosome 9p24.1 locus, the location of

Keywords

PD-1, PD-L1, CD30, large cell lymphoma

Published Open-Access

yes

Recommended Citation

Xie, Wei; Medeiros, L Jeffrey; Li, Shaoying; et al., "PD-1/PD-L1 Pathway: A Therapeutic Target in CD30+ Large Cell Lymphomas" (2022). Faculty, Staff and Student Publications. 2411.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/2411